Ethypharm announces the total acquisition of the share capital of DBA Group (DBA), a branded pharmaceutical business established in the UK in 2009.
Currently, DBA markets and supplies a range of prescription only medicines to the UK market, which generates generating significant savings for the National Health Service (NHS). They also have a pipeline of products in development that will be supplemented with a wide range of additional products from the Ethypharm pipeline.
Through the acquisition of DBA, Ethypharm continues to implement its strategy: development of a direct commercial presence in key territories in Europe to market Central Nervous System products. The company focuses in particular on pain and innovative treatments for addiction. DBA provides a pivotal platform to generate revenues in the important UK market. They predict that this acquisition, along with the deployment of its own commercial operations in France and Germany, will generate a turnover of more than € 240 million for Ethypharm.
“I am delighted to welcome the DBA team to the Ethypharm group,” said Hugues Lecat, CEO of Ethypharm. “The acquisition of DBA is a significant step forward for us. The know-how and expertise of both companies are totally complementary and synergistic and DBA offers a great platform to launch products from our own pipeline.”
Spherix Global Insights
Spherix Global Insights has acquired Rare Insights LLC, an insight and strategy group with a unique focus on rare and complex conditions.
Owner and President of Spherix Global Insights, Jennifer Robinson, said, “This acquisition accelerates our plans to add syndicated and custom patient insights to our suite of products. With the voice of the patient becoming an increasingly important consideration in drug development, we see an opportunity to offer clients insight and guidance about this important decision-making group.”
Robbie McCarthy, owner and principal of Rare Insights LLC, joins the senior management team of Spherix Global Insights as VP of Patient Insights and Rare Diseases. According to McCarthy, “Working with patients and caregivers living with rare or complex diseases requires a different approach. The communities are fractured, people are confused, isolated and vulnerable. They often need to seek out others like them for insight and support. They become experts in their own conditions and as such they are highly influential when it comes to treatment choice and use. Our unique approach enables us to recruit those hard to find patients and uncover critical insights into the beliefs and behaviors that patients have about their disease and related treatments. With our proprietary interpretive frameworks and our extensive commercial experience, we are able to bridge from insights to real world recommendations that can inform successful drug development, strategy and marketing, and that’s really what clients want and need.”
The initial focus will be on developing the Patient Dynamix offering for patients with complex diseases in our core specialty areas of nephrology, neurology, pulmonology, and rheumatology. The Patient Dynamix series will leverage the Spherix Network, a proprietary group of highly engaged physicians and patients, to intimately understand the impact of the treatment paradigm from both the patient and physician vantage points.